Pharma Markets

Global Age-Related Macular Degeneration Market and Competitive Landscape

By Fore Pharma | Published Date: June 7, 2020 | On-Demand Data

The latest research from Fore Pharma, Global Age-Related Macular Degeneration Market and Competitive Landscape – 2020, provides comprehensive insights into Age-Related Macular Degeneration pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares. This research analyzes and forecast Age-Related Macular Degeneration market size and drug sales. It also provides insights into Age-Related Macular Degeneration epidemiology and late stage pipeline.

This research covers the following – Age-Related Macular Degeneration treatment options, Age-Related Macular Degeneration late stage clinical trials pipeline, Age-Related Macular Degeneration prevalence by countries, Age-Related Macular Degeneration market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries. The research scope includes the countries US, Germany, France, Italy, Spain, UK, Japan, Europe, Global (G7 Countries).

Research Scope:

– Countries: US, Germany, France, Italy, Spain, UK, Japan, Europe, Global
– Age-Related Macular Degeneration pipeline: Find out drugs in clinical trials for Age-Related Macular Degeneration by development phase 3, phase 2, and phase 1, by pharmacological class and company
– Age-Related Macular Degeneration epidemiology: Find out number of patients diagnosed (prevalence) with Age-Related Macular Degeneration by countries
– Age-Related Macular Degeneration drugs: Identify key drugs marketed and prescribed for Age-Related Macular Degeneration by countries, including trade name, molecule name, and company
– Age-Related Macular Degeneration drugs sales: Find out the sales value for Age-Related Macular Degeneration drugs by countries
– Age-Related Macular Degeneration market valuations: Find out the market size for Age-Related Macular Degeneration drugs in 2019 by countries. Find out how the market advanced from 2016 and forecast to 2025
– Age-Related Macular Degeneration drugs market share: Find out the market shares for key drugs by countries

Benefits of this Research: The research helps executives to

– Evaluate commercial market opportunities for Age-Related Macular Degeneration drugs
– Synthesize insights for business development & licensing
– Track market size, competitor drug sales, market shares in Age-Related Macular Degeneration market
– Develop in-depth knowledge of competition and markets
– Analyze Age-Related Macular Degeneration drug sales data to update your brand planning trackers
– Develop tactics and strategies to take advantage of opportunities in the market
– Track Market Events and Trends and analyze key events in Age-Related Macular Degeneration market
– Develop forecast models, healthcare frameworks, or economic models
– Answer key business questions; supports decision making in R&D to long term marketing strategies

Table of Contents


1. Age-Related Macular Degeneration Treatment Options
2. Age-Related Macular Degeneration Pipeline Insights
2.1. Age-Related Macular Degeneration Phase 3 Clinical Trials
2.2. Age-Related Macular Degeneration Phase 2 Clinical Trials
2.3. Age-Related Macular Degeneration Phase 1 Clinical Trials
3. Age-Related Macular Degeneration Epidemiology Analysis by Countries
4. US Age-Related Macular Degeneration Market Insights
4.1. Marketed Drugs for Age-Related Macular Degeneration in US
4.2. US Age-Related Macular Degeneration Market Size & Forecast
4.3. US Age-Related Macular Degeneration Drugs Sales & Forecast
4.4. US Age-Related Macular Degeneration Market Share Analysis
5. Germany Age-Related Macular Degeneration Market Insights
5.1. Marketed Drugs for Age-Related Macular Degeneration in Germany
5.2. Germany Age-Related Macular Degeneration Market Size & Forecast
5.3. Germany Age-Related Macular Degeneration Drugs Sales Forecast
5.4. Germany Age-Related Macular Degeneration Market Share Analysis
6. France Age-Related Macular Degeneration Market Insights
6.1. Marketed Drugs for Age-Related Macular Degeneration in France
6.2. France Age-Related Macular Degeneration Market Size & Forecast
6.3. France Age-Related Macular Degeneration Product Sales Forecast
6.4. France Age-Related Macular Degeneration Market Share Analysis
7. Italy Age-Related Macular Degeneration Market Insights
7.1. Marketed Drugs for Age-Related Macular Degeneration in Italy
7.2. Italy Age-Related Macular Degeneration Market Size & Forecast
7.3. Italy Age-Related Macular Degeneration Product Sales Forecast
7.4. Italy Age-Related Macular Degeneration Market Share Analysis
8. Spain Age-Related Macular Degeneration Market Insights
8.1. Marketed Drugs for Age-Related Macular Degeneration in Spain
8.2. Spain Age-Related Macular Degeneration Market Size & Forecast
8.3. Spain Age-Related Macular Degeneration Product Sales Forecast
8.4. Spain Age-Related Macular Degeneration Market Share Analysis
9. UK Age-Related Macular Degeneration Market Insights
9.1. Marketed Drugs for Age-Related Macular Degeneration in UK
9.2. UK Age-Related Macular Degeneration Market Size & Forecast
9.3. UK Age-Related Macular Degeneration Product Sales Forecast
9.4. UK Age-Related Macular Degeneration Market Share Analysis
10. Europe Age-Related Macular Degeneration Market Insights
10.1. Europe Age-Related Macular Degeneration Market Size & Forecast
10.2. Europe Age-Related Macular Degeneration Product Sales Forecast
10.3. Europe Age-Related Macular Degeneration Market Share Analysis
11. Japan Age-Related Macular Degeneration Market Insights
11.1. Marketed Drugs for Age-Related Macular Degeneration in Japan
11.2. Japan Age-Related Macular Degeneration Market Size & Forecast
11.3. Japan Age-Related Macular Degeneration Product Sales Forecast
11.4. Japan Age-Related Macular Degeneration Market Share Analysis
12. Global Age-Related Macular Degeneration Market Insights
12.1. Global Age-Related Macular Degeneration Market Size & Forecast
12.2. Global Age-Related Macular Degeneration Product Sales Forecast
12.3. Global Age-Related Macular Degeneration Market Share Analysis
13. Research Methodology

List of Tables


1: Age-Related Macular Degeneration Phase 3 Clinical Trials, Global, 2020
2: Age-Related Macular Degeneration Phase 2 Clinical Trials, Global, 2020
3: Age-Related Macular Degeneration Phase 1 Clinical Trials, Global, 2020
4: Age-Related Macular Degeneration Prevalence by Countries, 2016 – 2025
5: Marketed Drugs for Age-Related Macular Degeneration in US, 2019
6: US Age-Related Macular Degeneration Market Size & Forecast ($mn), 2016 – 2025
7: US Age-Related Macular Degeneration Product Sales ($mn), 2016 – 2025
8: US Age-Related Macular Degeneration Market Events and Trends, 2016 – 2025
9: Marketed Drugs for Age-Related Macular Degeneration in Germany, 2019
10: Germany Age-Related Macular Degeneration Market Size & Forecast ($mn), 2016 – 2025
11: Germany Age-Related Macular Degeneration Product Sales ($mn), 2016 – 2025
12: Germany Age-Related Macular Degeneration Market Events and Trends, 2016 – 2025
13: Marketed Drugs for Age-Related Macular Degeneration in France, 2019
14: France Age-Related Macular Degeneration Market Size & Forecast ($mn), 2016 – 2025
15: France Age-Related Macular Degeneration Product Sales ($mn), 2016 – 2025
16: France Age-Related Macular Degeneration Market Events and Trends, 2016 – 2025
17: Marketed Drugs for Age-Related Macular Degeneration in Italy, 2019
18: Italy Age-Related Macular Degeneration Market Size & Forecast ($mn), 2016 – 2025
19: Italy Age-Related Macular Degeneration Product Sales ($mn), 2016 – 2025
20: Italy Age-Related Macular Degeneration Market Events and Trends, 2016 – 2025
21: Marketed Drugs for Age-Related Macular Degeneration in Spain, 2019
22: Spain Age-Related Macular Degeneration Market Size & Forecast ($mn), 2016 – 2025
23: Spain Age-Related Macular Degeneration Product Sales ($mn), 2016 – 2025
24: Spain Age-Related Macular Degeneration Market Events and Trends, 2016 – 2025
25: Marketed Drugs for Age-Related Macular Degeneration in UK, 2019
26: UK Age-Related Macular Degeneration Market Size & Forecast ($mn), 2016 – 2025
27: UK Age-Related Macular Degeneration Product Sales ($mn), 2016 – 2025
28: UK Age-Related Macular Degeneration Market Events and Trends, 2016 – 2025
29: Europe Age-Related Macular Degeneration Market Size & Forecast ($mn), 2016 – 2025
30: Europe Age-Related Macular Degeneration Product Sales ($mn), 2016 – 2025
31: Marketed Drugs for Age-Related Macular Degeneration in Japan, 2019
32: Japan Age-Related Macular Degeneration Market Size & Forecast ($mn), 2016 – 2025
33: Japan Age-Related Macular Degeneration Product Sales ($mn), 2016 – 2025
34: Japan Age-Related Macular Degeneration Market Events and Trends, 2016 – 2025
35: Global Age-Related Macular Degeneration Market Size & Forecast ($mn), 2016 – 2025
36: Global Age-Related Macular Degeneration Product Sales ($mn), 2016 – 2025

List of Figures


1: Age-Related Macular Degeneration Pipeline by Phase (%), Global, 2020
2: Age-Related Macular Degeneration Prevalence by Countries, 2016 – 2025
3: US Age-Related Macular Degeneration Market Size ($mn), 2016 – 2025
4: US Age-Related Macular Degeneration Product Sales ($mn), 2016 – 2025
5: US Age-Related Macular Degeneration Market Share by Drugs (%), 2019
6: US Age-Related Macular Degeneration Market – Future Market Share (%), 2025
7: Germany Age-Related Macular Degeneration Market Size ($mn), 2016 – 2025
8: Germany Age-Related Macular Degeneration Product Sales ($mn), 2016 – 2025
9: Germany Age-Related Macular Degeneration Market Share by Drugs (%), 2019
10: Germany Age-Related Macular Degeneration Market – Future Market Share (%), 2025
11: France Age-Related Macular Degeneration Market Size ($mn), 2016 – 2025
12: France Age-Related Macular Degeneration Product Sales ($mn), 2016 – 2025
13: France Age-Related Macular Degeneration Market Share by Drugs (%), 2019
14: France Age-Related Macular Degeneration Market – Future Market Share (%), 2025
15: Italy Age-Related Macular Degeneration Market Size ($mn), 2016 – 2025
16: Italy Age-Related Macular Degeneration Product Sales ($mn), 2016 – 2025
17: Italy Age-Related Macular Degeneration Market Share by Drugs (%), 2019
18: Italy Age-Related Macular Degeneration Market – Future Market Share (%), 2025
19: Spain Age-Related Macular Degeneration Market Size ($mn), 2016 – 2025
20: Spain Age-Related Macular Degeneration Product Sales ($mn), 2016 – 2025
21: Spain Age-Related Macular Degeneration Market Share by Drugs (%), 2019
22: Spain Age-Related Macular Degeneration Market – Future Market Share (%), 2025
23: UK Age-Related Macular Degeneration Market Size ($mn), 2016 – 2025
24: UK Age-Related Macular Degeneration Product Sales ($mn), 2016 – 2025
25: UK Age-Related Macular Degeneration Market Share by Drugs (%), 2019
26: UK Age-Related Macular Degeneration Market – Future Market Share (%), 2025
27: Europe Age-Related Macular Degeneration Market Size ($mn), 2016 – 2025
28: Europe Age-Related Macular Degeneration Product Sales ($mn), 2016 – 2025
29: Europe Age-Related Macular Degeneration Market Share by Drugs (%), 2019
30: Europe Age-Related Macular Degeneration Market – Future Market Share (%), 2025
31: Japan Age-Related Macular Degeneration Market Size ($mn), 2016 – 2025
32: Japan Age-Related Macular Degeneration Product Sales ($mn), 2016 – 2025
33: Japan Age-Related Macular Degeneration Market Share by Drugs (%), 2019
34: Japan Age-Related Macular Degeneration Market – Future Market Share (%), 2025
35: Global Age-Related Macular Degeneration Market Size ($mn), 2016 – 2025
36: Global Age-Related Macular Degeneration Product Sales ($mn), 2016 – 2025
37: Global Age-Related Macular Degeneration Market Share by Drugs (%), 2019
38: Global Age-Related Macular Degeneration Market – Future Market Share (%), 2025

Format


Dispatch format is XLSX.

Purchase Checkout Added to cart
face
  • Contact Nick
  •  Email
  •  Contact
  • I was looking for specific epidemiology and utilization data for our emerging therapy situation analysis. It was time sensitive. Your team helped me with the right data and methodologies. Thank you very much.
    - Director, Big Pharma

    About

    • About us
    • Research Store
    • Research Store
    • News
    • Contact

    Trusted By
    Top Companies